Ranbaxy Laboratories and Daiichi Sankyo announced that the portfolio of the Daiichi Sankyo would be commercialized in Mexico through a recently created marketing division within Ranbaxy Mexico S.A. De C.V, a subsidiary of Ranbaxy.
This hybrid model will enable the companies to leverage their respective strengths in dominant prescription segment, through the newly created division, while continuing expansion in the rapidly evolving Generics market.
For comments and feedback: editorial@rttnews.com